Lysophosphatidylcholine is increased in the plasma of hypercholesterolemic patients, is a component of oxidatively modified low-density lipoprotein, and, as such, may play an important role in atherosclerosis. Here we demonstrate that in human monocytes, lysophosphatidylcholine increases the level of mRNA encoding the heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent smooth muscle mitogen. Lysophosphatidylcholine treatment also enhances the release of heparin-binding mitogenic activity by these cells in culture. The anti-inflammatory glucocorticoid dexamethasone inhibits the upregulation of HB-EGF mRNA induced by either lysophosphatidylcholine or bacterial lipopolysaccharide in cultured monocytes. However, the responses induced by lysophosphatidylcholine and by lipopolysaccharide differ in their kinetics. In addition, the response to lysophosphatidylcholine is resistant to the action of cycloheximide, whereas the response to lipopolysaccharide is not, suggesting that the activation mechanisms induced by these two stimuli are different. Since a nuclear run-on assay showed no effect of lysophosphatidylcholine on the transcription of the HB-EGF gene, we speculate that lysophosphatidylcholine may increase the level of HB-EGF mRNA by altering the processing or degradation of primary or mature transcripts. Lysophosphatidylcholine enhancement of monocyte production of HB-EGF may represent an important result of the interactions among oxidized low-density lipoprotein and monocyte-derived macrophages and may play a role in initiation of smooth muscle proliferation in atherogenesis.
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The advanced lesions of atherosclerosis result from intimal accumulation of smooth muscle cells (SMCs), monocytes/ macrophages, connective tissue, and lipids. The increased number of SMCs within the intima results from the response of these cells to a number of growth-regulatory molecules that may be released by arterial cells or cells from the circulation. Since attachment of monocytes to the artery wall and monocyte infiltration into the intima are among the earliest events in the development of the lesions of atherosclerosis (1) , monocytes/macrophages may be important early sources of substances that can induce chemotaxis and proliferation of both monocytes and SMCs.
One of the candidate monocyte/macrophage-derived growth factors for SMCs is a macrophage-derived mitogen, heparin-binding epidermal growth factor-like growth factor (HB-EGF), which stimulates the proliferation of fibroblasts and SMCs and migration of SMCs in vitro. Although the actions of HB-EGF appear to be mediated by binding of HB-EGF to the epidermal growth factor (EGF) receptor, HB-EGF is much more potent than EGF as a mitogen and chemoattractant for SMCs (2, 3 (4) . Intensive lipid-lowering therapy has been shown to enhance the regression of coronary artery disease (5). However, although hyperlipidemia is important in the development of atherosclerosis, the mechanisms which link hyperlipidemia and SMC proliferation remain to be clarified.
A large amount of data from experimental animals has implicated oxidized LDL as a principal lipid mediator of lesion formation in atherosclerosis (6) . However, in vitro studies with oxidized LDL have demonstrated variability in biological activities among laboratories and different preparations (7) . We therefore investigated whether the phospholipid lysophosphatidylcholine (lysoPC), a major component of oxidized LDL, activates monocytes/macrophages and stimulates their production ofgrowth factors. Here we report that lysoPC elevates levels of HB-EGF mRNA and stimulates the release of heparin-binding mitogenic activity from human monocytes. We discuss possible mechanisms for the production oflysoPC in the lesions of atherosclerosis and the possible role of lysoPC in initiation of the proliferative response by SMCs. (10) .
MATERIALS AND METHODS
Northern Blotting. Total cellular RNA was extracted (11), and samples (10 pg per lane) were run in 1% agarose/2.2 M formaldehyde gels and transferred to nylon membranes (Nytran, Schleicher & Schuell) (12) . After UV crosslinking, reversible RNA staining with methylene blue was performed to check the amount and quality of RNA (13) . After destaining, the membranes were subjected to hybridization (14) with probes labeled with [t-32P]dCTP (Amersham) by means of a random primer labeling system (Amersham). After hybridization, the membranes were washed with 2x standard saline citrate (SSC)/0.1% SDS at room temperature and with 0.2x SSC/0.1% SDS at 650C prior to autoradiography. For reprobing, blots were stripped with two 30-min washes with 0.02x SSC/0.1% SDS at 900C. All blots were rehybridized with (3-actin cDNA or glyceraldehyde-3-phosphate dehydrogenase cDNA probes to verify the mRNA load.
Transcriptional Analysis. A nuclear run-on assay was conducted (15) (Fig. 1) . In this experiment, 37.5 ug/ml was the optimal concentration of lysoPC for induction of HB-EGF mRNA (4.1-fold, from densitometric scans of the films that included a film from reprobing the same blots with (-actin cDNA to normalize for load differences). Although 1-actin mRNA levels were not affected, there was some variation in the optimal concentration, as well as the degree of mRNA upregulation, between experiments (data not shown). This may be due in part to variable uptake and modification of lysoPC by the cells, which may alter the concentration of lysoPC in the medium. Neither lysoPC nor the diluent (ethanol) had any effect on the viability of the cells as measured by trypan blue exclusion.
Although HB-EGF was originally described as a monocyte/macrophage-derived growth factor, it is also produced by SMCs (16, 17) . In contrast to monocytes, the HB-EGF mRNA level in SMCs was not affected by lysoPC (Fig. 1) . Screfton of HB-EGF-Like Activity from Monocytes Is Increased by LysoPC. To examine the release of growthstimulatory molecules from monocytes, we used heparinsepharose to fractionate the conditioned media of lysoPCtreated and control monocytes. Incubation of monocytes with lysoPC significantly increased the heparin-binding mitogenic activity in the conditioned medium, and the release of mitogenic activity was well correlated with the HB-EGF mRNA level (Fig. 3) (Fig. 4) . To further characterize the mechanism of mRNA increase, we examined the effects of several agents on the upregulation of HB-EGF mRNA by either lysoPC or LPS. First, we examined the effect of dexamethasone, a synthetic glucocorticoid, on HB-EGF mRNA levels. Dexamethasone completely inhibited both lysoPC-and LPS-induced upregulation of HB-EGF mRNA (Fig. 4A) . Consistent with these results, dexamethasone has also been shown to downregulate the expression of HB-EGF mRNA in both unstimulated and thrombin-stimulated cultured human SMCs (17 We next determined whether de novo protein synthesis was necessary for the upregulation of HB-EGF mRNA observed at 24 hr. Cycloheximide, an inhibitor of protein synthesis, did not inhibit the lysoPC enhancement of HB-EGF mRNA, whereas it completely blocked the LPS effect (Fig. 4B) . The level of HB-EGF mRNA was also enhanced by interleukin 1P, and this effect was inhibited by cycloheximide (data not shown).
To further examine the different cycloheximide susceptibilities of the lysoPC and LPS effects, we studied the time course of regulation of HB-EGF mRNA levels in lysoPC-or LPS-stimulated monocytes (Fig. 5) . The level ofthe HB-EGF mRNA was relatively high just after the preparation of monocytes (at 0 hr) and remained relatively high. However, in the absence of lysoPC or LPS, the level decreased during further incubation. The level of HB-EGF mRNA immediately following isolation was variable among donors but did not appear to be due to endotoxin contamination of reagents, which were all monitored. In the presence of lysoPC, upregulation was observed at 3 hr and was maintained for at least 24 hr. Cycloheximide did not affect the time course of the lysoPC-induced upregulation (data not shown). On the other hand, in the LPS-stimulated monocytes, the mRNA level Proc. Natil. Acad. Sci. USA 91 (1994) reached a maximum at 1 hr, decreased to a low level at 3 hr, and increased again after 8 hr. In the presence of cycloheximide, LPS induced the first peak but did not induce the second, indicating that the second increase in HB-EGF mRNA was dependent on de novo protein synthesis.
Effect of LysoPC on Transcription of the HBB-EGF Gene and
Stability of BB-EGF mRNA. To examine the effect of lysoPC on transcription of the HB-EGF gene, we performed nuclear run-on assays (Fig. 6) . LysoPC did not enhance transcription at 3 hr or at 24 hr, whereas dexamethasone inhibited HB-EGF mRNA transcription.
We also examined the effect of lysoPC on mRNA stability in the presence ofan inhibitor ofRNA synthesis, actinomycin D (Fig. 7) . LysoPC had no effect on the decrease of HB-EGF mRNA observed in the presence of actinomycin D.
DISCUSSION
LysoPC and HB-EGF as Potential Mediators of the Developnment of Atherosclerotic Lesions. It has been reported that lysoPC is a chemoattractant for human monocytes (18) and that it enhances expression of the cell adhesion molecules VCAM-1 and ICAM-1 in cultured human umbilical vein endothelial cells (19) . Such an-effect could increase the adherence of monocytic cells to the endothelium if it occuffed in vivo. The data reported here demonstrate that lysoPC stimulates monocytes to release EGF-like heparinbinding mitogenic activity and to upregulate mRNA of HB-EGF, a potent mitogen for SMCs.
Heparin-binding EGF is a member of a family of molecules structurally similar to EGF that include transforming growth factor a, amphiregulin, and the poxvirus growth factors (20) . In addition to sharing structural similarities, these distinct gene products all bind with high affinity to the EGF receptor. However, HB-EGF stimulates SMC proliferation to a level comparable to that observed in'response to platelet-derived growth factor and is much m"re potent than other members of the EGF family (3). This appears in part to be due to its ability to bind heparin, although this is also a property of amphiregulin, which binds the EGF receptor with a lower affinity than other EGF family members (21) . The enhanced response to HB-EGF observed in SMCs appears to be mediated by a dual receptor system requiring interaction with both cell surface glycosaminoglycans and the EGF receptor (22) , similar to the dual receptor system required for activity ofbasic fibroblast growth Actor (23) . HB-EGF may also have a distinct receptor in addition to the EGF receptor.
A recent survey of human thoracic and abdominal aortae obtained from individuals from 2 in atherosclerotic plaques, marked production of HB-EGF protein was detected in both SMCs and macrophages. In addition, EGF receptors were detected on SMCs in the lesions, many of which were positive for proliferating-cell nuclear antigen, an index of cycling cells. Thus, the association of HB-EGF protein and the EGF receptor with lesions of atherosclerosis is consistent with a potential role for HB-EGF in SMC migration and proliferation, characteristic of these developing lesions.
Mechanism of Upregulation of HB-EGF mRNA. HB-EGF mRNA in monocytes can be upregulated by lysoPC as well as by LPS. However, the differences in time course and susceptibility to cycloheximide suggest that lysoPC and LPS upregulate HB-EGF mRNA via different mechanisms. Inhibition of the second peak of LPS-induced HB-EGF mRNA expression by cycloheximide suggests that the second response requires protein synthesis, whereas upregulation by lysoPC is independent of protein synthesis.
In evaluating the mechanism of lysoPC alteration of HB-EGF mRNA levels, we performed nuclear run-on assays to investigate transcriptional regulation. We could not detect enhancement of transcription of HB-EGF at 3 or 24 hr after stimulation with lysoPC, although we did detect downregulation by the glucocorticoid dexamethasone (Fig. 6 ). As noted above, lysoPC enhancement of HB-EGF mRNA levels is not dependent upon protein synthesis, nor is the stability of mature mRNA altered in the presence of the RNA synthesis inhibitor actinomycin D. It is possible that lysoPC may alter the processing or degradation ofprimary or mature HB-EGF mRNA, but this effect may be inhibited by actinomycin D. This lysoPC inhibition of HB-EGF mRNA degradation or processing would depend upon the stability of some form of RNA. Further experiments will be required to determine the nature of'the RNA and whether this suggestion is correct.
Formation ofLysoPC in Atherosclerosis. Hydrolysis offatty acid on the sn-2 position of phospholipids is a key step in the formation of lysophospholipids. Lecithin-cholesterol acyltransferase (LCAT; phosphatidylcholine:sterol acyltransferase, EC 2.3.1.43) can hydrolyze the sn-2 fatty acid of phosphatidylcholine, transfer the fatty acid to cholesterol (24) , and produce lysoPC. LCAT is present in plasma, and highdensity lipoprotein enhances the catalytic activity of LCAT (25) . Higher LCAT activity has been observed in the plasma of atherosclerotic patients, who also have higher concentrations of lysoPC (26) , suggesting that LCAT may be a major factor in the production of lysoPC in these patients.
Oxidative modification of LDL has been proposed as a possible contributor to the development of atherosclerosis (6) . In vitro, oxidized LDL stimulates expression of colonystimulating factors in endothelial cells (27) and acts as a chemoattractant for human monocytes (28) . However, in vitro studies with oxidized LDL have demonstrated variability in biological activities among laboratories and different preparations (7). We have, therefore, focused these studies on a major component of oxidized LDL. Oxidation of LDL is a major source of phospholipids, especially in the plasma of hyperlipidemic individuals. During the oxidation of LDL, as much as 40o of the phosphatidyicholine of LDL may be converted to lysoPC (29) .
The biological activities of lysoPC presented here and in other papers (18, 19) suggest that lysoPC may contribute to the atherogenic activities ofoxidized LDL. It has been shown that apolipoprotein B in LDL possesses phospholipase A2 activity. Thus, the increased lysoPC content ofoxidized LDL may be due to the hydrolysis of phosphatidylcholine in LDL by the phospholipase A2 activity of apolipoprotein B (30) . Since LDL can be oxidatively modified by the cells in or around the lesions of atherosclerosis (31) (32) (33) , and since oxidatively modified LDL is present in the lesions (34) (35) (36) (37) , lysoPC in oxidized LDL may be important in the activation of monocytes/macrophages in the lesions.
The Fatty Acid Chain Length of LysoPC Is Important. The signal trasduction mechanisms responsible for the upregulation of HB-EGF mRNA in human monocytes by lysoPC may be an important issue to study. HB-EGF can act as a chemoattractant for human monocytes, and it has been postulated that generation of diacylglycerol, an activator of protein kinase C, through a mechanism involving lysophospholipase C, may be involved in lysoPC-induced chemotaxis (38) . However, our preliminary experiments using a synthetic diacylglycerol did not demonstrate upregulation of HB-EGF mRNA in human monocytes (data not shown). This suggests, therefore, that, different from chemotaxis, HB-EGF mRNA induction may not involve protein kinase C.
Our data showed that a small difference in the fatty acid chain length of lysoPC caused a profound difference in potency of lysoPC in upregulating HB-EGF mRNA. Stearoyl lysoPC upregulated the mRNA, but palmitoyl lysoPC did not. Although the precise mechanism for the action of lysoPC is not clear, a small difference in the physical property of lysoPC appears to be important for upregulation of HB-EGF mRNA in monocytes. LysoPC also induces expression of an adhesion-molecule gene in human endothelial cells (19) . In this case, however, palmitoyl lysoPC induces the expression of the adhesion molecule. This difference in effect of fatty acid chain length on these two human cells may suggest that the molecular mechanism for HB-EGF induction in monocytes is different from the mechanism that induces adhesionmolecule expression in endothelial cells.
To further clarify the importance of lysoPC in vivo, it will be necessary to develop specific agents that inactivate lysoPC or inhibit LCAT and phospholipase A2. Such agents may be capable of altering the development of lesions of atherosclerosis as well as other inflammatory fibroproliferative responses.
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